Next Article in Journal
Crohn’s Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches
Next Article in Special Issue
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study
Previous Article in Journal
Association of Circulating Endothelial Nitric Oxide Synthase Levels with Phosphataemia in Patients on Haemodialysis
Previous Article in Special Issue
Hsa_circ_0092856 Promoted the Proliferation, Migration, and Invasion of NSCLC Cells by Up-Regulating the Expression of eIF3a
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 3
10.3390/biomedicines12030688
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy

by
Jan Nicolai Wagner
1,*,
Julia Roeper
1,
Lukas Heukamp
2,
Markus Falk
2,
Kay Willborn
3 and
Frank Griesinger
4
1
Faculty VI—Medicine and Health Sciences, European Medical School, University Oldenburg, Ammerländer Heerstraße 114-118, 26129 Oldenburg, Germany
2
Hematopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany
3
Department of Radiotherapy and Radio-Oncology, University Department of Medical Radiation Physics, Pius-Hospital Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany
4
Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(3), 688; https://doi.org/10.3390/biomedicines12030688
Submission received: 10 February 2024 / Revised: 8 March 2024 / Accepted: 13 March 2024 / Published: 19 March 2024
(This article belongs to the Special Issue Understanding Non-small Cell Lung Cancer: Biology, Therapeutics and Drug Resistance)
Browse Figures
Review Reports Versions Notes

Abstract

Background: The PACIFIC study showed that after radio-chemotherapy, patients with NSCLC derived a benefit in PFS and OS when treated with durvalumab. This effect was limited to patients with a PD-L1 expression of >1%, partly because the outcome in the observational control arm was surprisingly favorable. Thus, it could be speculated that a lack of PD-L1 expression confers a favorable outcome for patients with stage III NSCLC. Methods: Clinical data, PD-L1 expression, predictive blood markers, and the outcomes of 99 homogeneously treated patients with stage III NSCLC were retrospectively captured. Statistical analyses using the log rank test were performed. Results: The median OS of patients with an expression of PD-L1 < 1% was 20 months (CI 10.5–29.5) and the median OS of patients with an expression of PD-L1 ≥ 1% was 28 months (CI 16.5–39.2) (p = 0.734). The median PFS of patients with an expression of PD-L1 < 1% was 9 months (CI 6.3–11.6) and the median PFS of patients with an expression of PD-L1 ≥ 1% was 12 months (CI 9.8–14.2) (p = 0.112). Conclusions: The assumption that the lack of PD-L1 expression represents a favorable prognostic factor after radio-chemotherapy vs. PD-L1 expression > 1% was not confirmed.
Keywords: local advanced NSCLC; stage III; PD-L1; radio-chemotherapy; lung cancer local advanced NSCLC; stage III; PD-L1; radio-chemotherapy; lung cancer

Share and Cite

MDPI and ACS Style

Wagner, J.N.; Roeper, J.; Heukamp, L.; Falk, M.; Willborn, K.; Griesinger, F. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy. Biomedicines 2024, 12, 688. https://doi.org/10.3390/biomedicines12030688

AMA Style

Wagner JN, Roeper J, Heukamp L, Falk M, Willborn K, Griesinger F. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy. Biomedicines. 2024; 12(3):688. https://doi.org/10.3390/biomedicines12030688

Chicago/Turabian Style

Wagner, Jan Nicolai, Julia Roeper, Lukas Heukamp, Markus Falk, Kay Willborn, and Frank Griesinger. 2024. "Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy" Biomedicines 12, no. 3: 688. https://doi.org/10.3390/biomedicines12030688

APA Style

Wagner, J. N., Roeper, J., Heukamp, L., Falk, M., Willborn, K., & Griesinger, F. (2024). Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy. Biomedicines, 12(3), 688. https://doi.org/10.3390/biomedicines12030688

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop